X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
A couple of drug industry trade groups sued the Trump administration separately in federal courts in Maryland and California, challenging new US rules to lower drug prices.
The plaintiffs were filed by the Pharmaceutical Research and Manufacturers of America (PhRMA), a pharmaceutical industry trade group, and biotechnology industry trade organizations.
The rule being challenged, which will take effect on Jan. 1, would tie payments for some drugs made by Medicare, a US government insurance program, to the lowest price paid by some countries.
According to the administration, the move could save taxpayers and patients $85 billion over seven years.
The PhRMA claims the rule change is illegal because it is too far-reaching to qualify as a pilot.
Steve Ubl, PhRMA’s CEO, said the rules could not be categorized as it impacts the entire country and implicates 90 percent of spending with no control group.
The Association of Community Cancer (ACC), which joined PhRMA in the suit, noted that lower reimbursements for drugs could put cancer treatment centers out of business, as many rely heavily on Medicare.
Both suits claim that the appropriate process in coming up with the rules was not followed, as it failed to collect feedback from stakeholders before its announcement.
